9
Frankfurt/Washington/Vienna-The US drug authority FDA has suspended the approval for the Chikungunya vaccine Ixchiq from the Austrian-French manufacturer Valneva developed in Vienna. The reason is reports of more than 20 serious side effects, including 21 hospital admissions and three deaths, one of them directly by an encephalitis triggered by the vaccine. Valneva must immediately hire the sale and delivery in the USA.
